565TiP A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2- breast cancer

Abramson, V., Linden, H. M., Crew, K., Mortimer, J., Alidzanovic, J., Nangia, J., Layman, R., Vranjes, Z. J., Andric, Z., Milovic-Kovacevic, M., Trifunovic, J., Karchmit, Y., Suarez, J., Suster, M., Ptaszynski, M., & Chalasani, P. (2021). 565TiP A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2- breast cancer. Annals of Oncology, 32, S619. https://doi.org/10.1016/j.annonc.2021.08.1087

Authors:

Vandana G. Abramson

Hannah M. Linden

Katherine D. Crew

Joanne Mortimer

Jasmina Alidžanović

Julie R. Nangia

Rachel M. Layman

Živko Vranješ

Zoran Andrić

Marijana Milović-Kovačević

J. Trifunovic